Coronavirus (COVID-19) News
Filter News
Found 2,541 articles
-
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
12/26/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines.
-
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
12/22/2022
Revive Therapeutics Ltd. announced that it has submitted the Type C meeting request package to the U.S. Food & Drug Administration to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
-
More exercise linked to less-severe COVID-19 outcomes
12/15/2022
Kaiser Permanente members who were more physically active prior to being diagnosed with COVID-19 had a lower risk of severe outcomes, according to research published Dec. 15, 2022, in the American Journal of Preventive Medicine.
-
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
12/14/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 vaccine ReCOV in the Philippines.
-
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
12/7/2022
Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19.
-
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
12/6/2022
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced new preclinical data showing KIN001’s strong antiviral efficacy against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5.
-
Eurofins Launches BQ.1 and BQ.1.1 Droplet Digital PCR Assay (ddPCR) for SARS-CoV-2 Wastewater Testing
12/5/2022
Eurofins Environment Testing Northern California: Wastewater and Eurofins Pandemic Prevention Services launched a droplet digital PCR assay for the combined quantitative analysis of SARS-CoV-2 Variants of Concern BQ.1 and BQ.1.1 in wastewater.
-
Pictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test
12/4/2022
$5 million raise to accelerate global market development & product development
-
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
12/1/2022
Halberd Corporation's Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
-
Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
12/1/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies
-
New Health+™ Long COVID Report Translates Lived Experiences into Evidence-Based Recommendations
11/30/2022
The US Department of Health and Human Services and its Office of the Assistant Secretary of Health recently released a Health+ Long COVID Human-Centered Design Report produced by Coforma's Health+™ program.
-
Dompé: New Published Data Point to Spike Protein Interactions with Estrogen Receptors as a cause for Coagulopathy in COVID-19 Patients, Signaling Sex Effects and a Path to Improved Vaccines
11/30/2022
Dompé farmaceutici announced new data revealing a novel function of the SARS-CoV-2 Spike protein interaction with the human Estrogen Receptor Alpha that may lead to the severe coagulopathy observed in patients with COVID-19 and a minority of subjects receiving the SARS-CoV-2 vaccine.
-
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
11/30/2022
Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.
-
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
11/29/2022
Novavax, Inc. announced that the World Health Organization has issued an updated Emergency Use Listing for Nuvaxovid™ COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.
-
In a volatile year, marked with challenges, BioSpace is taking a pause to reflect on the many “wins” in biopharma.
-
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
11/24/2022
Revive Therapeutics Ltd. announced that it will submit the Type C meeting request package to the US FDA by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
-
Sense and R-Biopharm Nederland B.V. Agree to Distribute Rapid, Instrument-Free Molecular COVID-19 Test in the Netherlands, Belgium, and Luxembourg
11/22/2022
Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with R-Biopharm Nederland B.V. for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, point-of-care molecular testing platform.
-
Pfizer and BioNTech reported positive data Friday from their Omicron BA.4/BA.5-adapted bivalent booster. This followed a similar announcement by Moderna Monday.
-
Therma Bright Inc. to Acquire an Exclusive License for a Patented Digital Cough Based Technology to Detect Respiratory Diseases
11/17/2022
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent ("LOI") with AI4LYF LLC ("AI4LYF") for the exclusive licensing rights for a digital cough-based diagnosis screening technology.